ARCHIVES

FDA Approves NDA For Mylan’s Paclitaxel For Ovarian And Breast Cancer Treatment.

This article is from The Cancer Letter archive.

Vol. 27 No. 30 | July 27, 2001

Download PDF Visit The Full Archive

Related Articles

Clarification: Full Text Of ACS Guideline On Prostate Screening

January 30, 1998

ODAC Okays First “Paper NDA,” By BMS For Bieomycin

October 1, 1993

NCI plans 18 percent budget cuts for large R01s, smaller cuts to other research project grants. NCI treatment division director Ellen Feigal accepts position with Translational Genomics Research Institute in Phoeniz, Ariz.

March 12, 2004

Carlson Named NCCN Chief Executive

September 28, 2012

MD Anderson Completes $500 Million Research Endowment

September 24, 2010

DeVita Appointment Now Official; Calls For New Chemoprevention Program, More Applied Prevention

July 18, 1980